One of the steepest decliners in the biotech sector Thursday was Epizyme (NASDAQ: EPZM). The cancer-focused biotech saw its shares plummet 44% in value that day, on news of a dilutive secondary stock issue. Epizyme announced that it is floating nearly 56.7 million shares of its stock, which will be sold in a public offering at $1.50 per share before underwriting discounts.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting